← Back to Home

Making Room for Children’s Growth: FDA Approves AUTUS Expandable Pulmonary Valve

The new valve can be expanded by catheter after implantation, offering the possibility of reducing repeat open-heart surgery for children with congenital heart disease. Short-term trial results support its function, but the durability of its polymer leaflets and the benefits of repeated expansion still require long-term follow-up.

By SURL BioNews

For children who need pulmonary valve replacement, a successful operation does not necessarily mean they can navigate the years of growth without further problems. As their bodies grow, a prosthetic valve that initially fit may become too small, making another operation a challenge. On October 1, the U.S. Food and Drug Administration (FDA) approved the AUTUS size-adjustable valve, giving physicians another option that can be expanded after implantation.

Developed by Autus Valve Technologies, the device received approval through Edwards Lifesciences and is intended for children with congenital heart disease who need pulmonary valve replacement. Initial implantation still requires surgery; afterward, the valve can be enlarged with a balloon through a minimally invasive catheter procedure. According to the FDA, its initial diameter can be as small as approximately 13 millimeters and can subsequently be expanded to 22 millimeters. Accommodating growth means adjusting its size through a medical procedure, rather than the valve growing on its own.

Another change lies in the leaflets that control blood flow. AUTUS uses a polymer, making it the first heart valve approved in the United States to use this type of leaflet material. Traditional animal-tissue valves are more prone to hardening and degeneration in children. The new material offers a different design approach, but one year of follow-up is not sufficient to establish whether it can withstand repeated opening, closing, and expansion over the long term.

The FDA’s approval was based in part on a study involving 62 children at 12 centers in the United States. At six-month follow-up, the first 60 patients to receive implants had acceptable blood flow performance through the valve, with no more than mild regurgitation. Edwards also stated that the study met its primary safety and effectiveness endpoints, with no device-related complications in any patient within 30 days and no reinterventions on the AUTUS valve within six months.

Beyond the short-term measures, the FDA also disclosed device issues requiring continued follow-up: three patients experienced valve frame fractures, and two patients had reduced movement of one leaflet. None of these issues caused symptoms at the time. In two other patients, valve function began to deteriorate as their bodies grew, and both subsequently underwent successful expansion. This provides initial experience with adjusting the valve’s size in practice, although the number of cases remains small.

Edwards stated that among patients who had completed one year of follow-up, all had a mean right ventricular outflow tract pressure gradient of no more than 40 millimeters of mercury, less than moderate pulmonary regurgitation, and no valve reinterventions. These results support early functional performance, but the announcement did not specify how many patients had completed one-year follow-up, so they cannot be taken directly as results for all 62 patients. Data from different follow-up time points also need to be interpreted separately.

Patients in the study will continue to be followed for ten years. For families, the most immediate hope is to reduce open-heart operations as their children grow. Whether that hope can be realized will depend on how long the valve continues to function after expansion, whether it can be safely expanded again, and whether changes in the frame and leaflets affect subsequent function. This approval opens up a new treatment option, while its long-term benefits remain to be established over time.

References

  1. FDA
  2. Edwards Lifesciences